Regeneron Pharmaceuticals Valuation

REGN -- USA Stock  

USD 286.15  1.09  0.38%

Regeneron Pharmaceuticals holds recent Real Value of $346.28 per share. The prevailing price of the company is $286.15. At this time the company appears to be undervalued. This module determines value of Regeneron Pharmaceuticals from analyzing the company fundamentals such as Operating Margin of 32.08%, Return On Equity of 24.43% and Shares Outstanding of 107.98M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Undervalued
September 19, 2019
286.15
Market Value
257.53
Downside
346.28
Real Value
351.68
Upside
Regeneron Pharmaceuticals is very steady asset. Calculation of real value of Regeneron Pharmaceuticals is based on 3 months time horizon. Increasing Regeneron Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
Regeneron Pharmaceuticals Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    

Regeneron Pharmaceuticals Market Cap

Regeneron Pharmaceuticals is rated third in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 179.38 Billion. Regeneron Pharmaceuticals retains roughly 31.4 Billion in market capitalization claiming about 18% of stocks in Biotechnology industry.
Capitalization  Workforce  Total debt  Revenue  Valuation
Horizon     30 Days    Login   to change
Regeneron Pharmaceuticals is rated third in price to earning category among related companies. It is rated third in price to book category among related companies fabricating about  0.20  of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for Regeneron Pharmaceuticals is roughly  4.96 

Valuation Basics

Regeneron Pharmaceuticals Enterprise Value Fundamentals

Quick Ratio3.01
Earnings Quarterly Growth-65.00%
Revenue Growth20.30%
Enterprise Value To Ebitda12.43
Earnings Growth-65.10%
Enterprise Value To Revenue3.99

Valuation Indicators

Regeneron Pharmaceuticals Valuation Fundamental Ratios

Additionally take a look at Your Equity Center. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.
Search macroaxis.com